In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Craig A. Dionne, PhD, CEO of GenSpera, describes some of the drawbacks associated with common cancer treatments. Many types of drug therapies, like antiangiogenics and immunotherapies, may only…
Mipsagargin (G-202), a new prodrug developed by GenSpera, has a unique mechanism of action that allows it to kill cancer cells without damaging surrounding tissues. Derived from thapsigargin,…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
